LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
Cancer Lett
; 503: 138-150, 2021 04 10.
Article
em En
| MEDLINE
| ID: mdl-33503448
ABSTRACT
The androgen receptor (AR) is expressed in prostate fibroblasts in addition to normal prostate epithelial cells and prostate cancer (PCa) cells. Moreover, AR activation in fibroblasts dramatically influences prostate cancer (PCa) cell behavior. Androgen deprivation leads to deregulation of AR downstream target genes in both fibroblasts and PCa cells. Here, we identified LIM domain only 2 (LMO2) as an AR target gene in prostate fibroblasts using ChIP-seq and revealed that LMO2 can be repressed directly by AR through binding to androgen response elements (AREs), which results in LMO2 overexpression after AR deactivation due to normal prostate fibroblasts to cancer-associated fibroblasts (CAFs) transformation or androgen deprivation therapy. Next, we investigated the mechanisms of LMO2 overexpression in fibroblasts and the role of this event in non-cell-autonomous promotion of PCa cells growth in the androgen-independent manner through paracrine release of IL-11 and FGF-9. Collectively, our data suggest that AR deactivation deregulates LMO2 expression in prostate fibroblasts, which induces castration resistance in PCa cells non-cell-autonomously through IL-11 and FGF-9.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Feniltioidantoína
/
Benzamidas
/
Receptores Androgênicos
/
Regulação para Cima
/
Proteínas Proto-Oncogênicas
/
Proteínas Adaptadoras de Transdução de Sinal
/
Proteínas com Domínio LIM
/
Neoplasias de Próstata Resistentes à Castração
/
Fibroblastos Associados a Câncer
/
Nitrilas
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article